5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter

Pharmaceutical Research

Volumn 15, Issue 8, 1998, Pages 1154-1159

  Han, Hyo Kyung ^a   De Vrueh, Remco L A ^b   Rhie, Julie K ^a,c   Covitz, Kuang Ming Y ^d   Smith, Philip L ^e   Lee, Chao Pin ^e   Oh, Doo Man ^a   Sadée, Wolfgang ^d   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Amino acid ester; PEPT1 transporter; Permeability; Prodrugs

Indexed keywords

ACICLOVIR; NUCLEOSIDE ANALOG; PRODRUG; ZIDOVUDINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG TRANSPORT; INTESTINE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS INFECTION;

NON-PROGRAMMATIC;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CARRIER PROTEINS; CHO CELLS; CRICETINAE; ESTERS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; RATS; SYMPORTERS; ZIDOVUDINE;

EID: 0031662109     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011919319810     Document Type: Article

References (27)

1. P. de Miranda and M. R. Blum. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12(suppl B):29-37 (1983).
2. M. A. Jacobson, P. de Miranda, D. M. Cederberg, T. Burnette, E. Cobb, H. R. Brodie, and J. Mills. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob. Agents Chemother. 31:1251-4 (1987).
3. A. P. Waclawski and P. J. Sinko. Oral absorption of anti-acquired immune deficiency syndrome nucleoside analogues. 2. Carrier-mediated intestinal transport of stavudine in rat and rabbit preparations. J. Pharm. Sci. 85:478-85 (1996).
4. E. Walter, T. Kissel, and G. L. Amidon. The intestinal peptide carrier: A potential transport system for small peptide derived drugs. Adv. Drug Del. Rev. 20:33-58 (1996).
5. J. P. F. Bai, B. H. Stewart, and G. L. Amidon. Gastrointestinal Transport of Peptide and Protein Drugs and Prodrugs. Handbk. Exp. Pharmacol. 110:189-206 (1994).
6. B. H. Stewart, A. R. Kugler, P. R. Thompson, and H. N. Bockbrader. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. 10:276-281 (1993).
7. F. H. Leibach and V. Ganapathy. Peptide transporters in the intestine and the kidney. Annu. Rev. Nutr. 16:99-119 (1996).
8. P. L. Smith, E. P. Eddy, C. -P. Lee, and G. Wilson. Exploitation of the intestinal oligopeptide transporter to enhance drug absorption. Drug. Del. 1:103-111 (1993).
9. M. Hu, P. Subramanian, H. I. Mosberg, and G. L. Amidon. Use of the peptide carrier system to improve the intestinal absorption of L-α-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-α-methyldopa. Pharm. Res. 6:66-70 (1989).
10. S. Weller, M. R. Blum, M. Doucette, T. Burnette, D. M. Cederberg, P. de Miranda, and M. L. Smiley. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single and multiple dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:595-605 (1993).
11. L. M. Beauchamp, G. F. Orr, P. de Miranda, T. Burnette, and T. A. Krenitsky. Amino acid ester prodrugs of acyclovir. Antiviral. Chem. Chemother. 3:157-164 (1992).
12. K. Y. Covitz, G. L. Amidon, and W. Sadée. Human dipeptide transporter, hPEPT1, stably transfected into chinese hamster ovary cells. Pharm. Res. 13:1631-1634 (1996).
13. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
14. G. J. Marks, F. M. Ryan, I. J. Hidalgo, and P. L. Smith. Mannitol as a marker for intestinal integrity in in vitro absorption studies. Gastroenterology 100:A697 (1991).
15. D. A. Johnson and G. L. Amidon. Determination of intrinsic membrane transport parameters from perfused intestine experiments: A boundary later approach to estimating the aqueous and unbiased membrane permeabilities. J. Theor. Biol. 131:93-106 (1988).
16. A. De Lean, P. J. Munson, and D. Rodbard. Simultaneous analysis of families of sigmoidgand assay and physiological dose-response curves. Am. J. of Physio. 235:E 97-102 (1978).
17. G. M. Grass and S. A. Sweetana. In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharm. Res. 5:372-376 (1988).
18. K. C. Meadows and J. B. Dressman. Mechanism of acyclovir uptake in rat jejunum. Pharm. Res. 7:299-303 (1990).
19. M. Hu. Comparison of uptake characteristics of thymidine and zidovudine in a human intestinal epithelial model system. J. Pharm. Sci. 82:829-833 (1993).
20. T. Okano, K. Inui, H. Maegawa, M. Takano, and R. Hori. H+ coupled uphill transport of aminocephalosporins via the dipeptide transport system in rabbit intestinal brush-border membranes. J. Biol. Chem. 261:14130-4 (1986).
21. D. I. Friedman and G. L. Amidon. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm. Res. 6:1043-7 (1989).
22. J. Samanen, G. Wilson, P. L. Smith, C. P. Lee, W. Bondinell, T. Ku, G. Rhodes, and A. Nichols. Chemical approaches to improve the oral bioavailability of peptidergic molecules. J. Pharm. Pharmacol. 48:119-35 (1996).
23. W. Kramer, F. Girbig, U. Gutjaha, H-W. Kleemann, I. Leipe, H. Urbach, and A. Wagner. Interaction of renin inhibitors with the intestinal uptake system for oligopeptides and beta-lactam antibiotics. Biochim. Biophys. Acta. 1027:25-30 (1990).
24. N. Hashimoto, T. Fujioka, K. Hayashi, K. Odaguchi, T. Toyoda, M. Nakamura, and K. Hirano. Renin inhibitor: relationship between molecular structure and oral absorption. Pharm. Res. 11:1443-7 (1994).
25. I. J. Hidalgo, P. Bhatnagar, C. P. Lee, J. Miller, G. Cucullino and P. L. Smith. Structural requirements for interaction with the oligopeptide transporter in Caco-2 cells. Pharm. Res. 12:317-9 (1995).
26. H. Bundgaard. Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities, in Design of Prodrugs, H. Bundgaard, Ed. (Elsevier, Amsterdam, The Netherlands), pp. 1-92 (1995).
27. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).